Consortium Seeks Best Treatment for HIV-positive Cancer Patients
Georgetown researcher says it is important to expand access for these patients to NCI sponsored clinical trials
June 7, 2010 - Washington, DC - Preliminary findings from a unique study with sunitinib suggest that it might be possible to
tweak the dosage of chemotherapy drugs used to treat HIV-positive cancer patients to achieve therapeutic benefit. Given the type of drug cocktail patients
use to treat their HIV, much more or considerably less chemotherapy may be warranted, say the researchers, part of the NCI-supported AIDS Malignancy
Consortium (AMC). The trial design is being presented at the 2010 annual meeting of the American Society
of Clinical Oncology (ASCO).
Researchers say the early analysis is important because it highlights the Catch 22 that many HIV-infected cancer patients face. "Cancer unrelated to AIDS
is rapidly increasing in HIV-positive patients, yet many oncologists do not know how to treat these cancers, and these patients are also excluded from cancer clinical
trials," says the study's lead investigator, John F. Deeken, M.D ., a
medical oncologist at Georgetown Lombardi Comprehensive Cancer Center.
"While such caution is understandable, it may be scientifically unjustified as well as fundamentally unfair, and this study is designed to help guide
treatment for these patients," says Deeken, who will present updated data on June 7 during the Trials in Progress Poster Session ASCO.
For reasons that are unclear, cancers that are unrelated to HIV infection are growing at an alarming rate in these patients, compared to the general
HIV-negative population, he says. These non-AIDS-defining cancers are also more aggressive, occur at younger ages, have higher rates of relapse and poorer
outcomes, Deeken says. For example, HIV patients are 13-31 times more likely to develop Hodgkin's lymphoma, they have a seven times higher rate of
developing liver cancer, and three times the rate of developing lung or head and neck cancers, he says.
"A key challenge in treating these patients is that anti-HIV medicines are notorious for causing drug-drug interactions. Such interactions with anti-cancer
chemotherapy drugs could lead to serious side effects and toxicities in patients," Deeken says.
This study is testing the safety of the chemotherapy drug sunitinib (Sutent) and has enrolled patients into two groups of HIV patients - group 1: those using
non-nuceleotide analog reverse transcription inhibitors (NNRTIs) in their drug cocktail and group 2: patients using ritonavir-based protease inhibitor cocktail therapy.
The AMC chose to study sunitinib because this oral medication was approved to treat kidney cancer, which is occurring at a higher rate among HIV patients, and
is being studied in other cancer types that also affect these patients, such as lung and colorectal. The study is being sponsored by the Division of Cancer Treatment
and Diagnosis, National Cancer Institute under a Clinical Trials Agreement with Pfizer, Inc for sunitinib.
Like many cancer drugs, sunitinib is a "prodrug" that requires the CYP450 family of enzymes in the liver to activate the drug for it to be effective. The
drugs used in the first group are not known to inhibit the liver enzymes but agents used in the second group are known to inhibit enzyme activity, which means that
cancer drugs that also use these enzymes could become too potent and therefore toxic, Deeken says.
Early findings from the nine patients enrolled to date indicate that the patients in the first group are tolerating standard sunitinib therapy. In fact,
the HIV cocktail used by some in the first group may be inducing liver enzyme activity which suggests that higher doses of sunitinib might be warranted in these
patients. It also appears that a low dose of sunitinib in the second group of patients is being highly activated, implying these patients could benefit from an even lower dose of chemotherapy.
The study will test the effects of different doses of sunitinib in participants, watching for toxicity as well as effectiveness.
"These are early days, but we hope the information we learn from this study will help these cancer patients get the therapy they want and need, as
well as access to clinical trials of the newest agents," Deeken says.
About the AIDS Malignancy Clinical Trials Consortium
The AIDS Malignancy Clinical Trials Consortium is a National Cancer Institute-supported clinical trials group founded in 1995 to support innovative trials for
AIDS-related cancers. The AMC is composed of over 37 Clinical Trials Sites worldwide. Sites which have enrolled patients onto this study include Georgetown,
Harvard's Beth Israel/Deaconess Medical Center, University of Pennsylvania, Virginia Mason Medical Center, and Washington University in St. Louis. The
study was funded by the National Cancer Institute. The authors declare no conflict of interest.
About Lombardi Comprehensive Cancer Center
The Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown
University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community
education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 41 comprehensive cancer centers in the nation, as
designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission
of research, teaching and patient care (through Georgetown's affiliation with MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a
dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of
Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization
(BGRO), home to 60 percent of the university's sponsored research funding.
Contact:
Karen Mallet (media only)
215-514-9751
km463@georgetown.edu
Reproduced with permission - "Georgetown University Medical Center"
Georgetown University Medical Center
| 
